Loading
A phase 2 trial of Visugromab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by CatalYm GmbH, now recruiting.
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC is a phase 2 interventional study registered as NCT07098988 by CatalYm GmbH, with 107 participants planned, started 2025-08-01 and due to reach its primary completion in 2029-03-31. Interventions recorded: Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2, Carboplatin AUC 5. Conditions listed: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor. No results are recorded here; the registry entry is the source.
Shares Visugromab, CatalYm, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.